Ipsen presents long-term IQIRVO data at liver disease conference

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. NDAQ
9. TSCO
10. BE

Go back to Ipsen presents long-term IQIRVO data at liver disease conference

Ipsen to present two late-breaking sessions at AASLD on new PBC data supporting IQIRVO®’s long-term efficacy, safety and mechanistic insights in fatigue

November 7, 2025 8:42 AM EST

Interim data from the IQIRVO® (elafibranor) ELATIVE long-term open label extension trial demonstrate sustained biochemical response, stabilization of fibrosis markers and consistent trends in improvement of fatigue and pruritus symptoms, with a well-characterized safety profile over more than three years of treatment  Additional new data from the ELATIVE trial highlights the potential for IQIRVO, a PPAR / agonist, to beneficially impact fatigue-associated pathways linked to mitochondrialfunction  

Paris, France  7 November, 2025 Ipsen (Euronext: IPN; ADR: IPSEY) today announced that new Primary Biliary Cholangitis (PBC) data with IQIRVO® from the... More